Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of September 2025, specifically detailing a share repurchase executed on August 29, 2025. The transaction was conducted through Merrill Lynch International under a non-discretionary agreement established on June 4, 2025.
Key Financial Metrics and Transaction Details
- Shares Purchased: 252,588 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,447.00 GBp; highest price paid was 1,461.50 GBp.
- Average Price: Volume-weighted average price paid was 1,454.14 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (CHIX or BATE).
- Treasury Share Holdings: Following this purchase, GSK holds 244,408,471 ordinary shares in treasury.
- Shares in Issue: 4,070,987,625 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.00% of total voting rights.
- Cumulative Buyback: Since the program inception on June 4, 2025, the company has purchased 26,274,088 ordinary shares.
Material Changes and Program Status
The filing confirms the continuation of GSK's existing share buyback program. The purchase of 252,588 shares on August 29, 2025, is a routine execution under the standing agreement with Merrill Lynch International. There are no material changes to the company's financial position, revenue, or profit reported in this specific filing, as it is limited to the disclosure of the share transaction. The filing notes that the purchased shares are held as Treasury shares and do not carry voting rights.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that could cause actual results to differ materially. Specific risk factors are referenced in the company's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025. No new guidance or specific management commentary regarding future financial performance is provided in this document.
Key Facts for Investor Verification
- Verify the total number of shares purchased under the buyback program since June 4, 2025 (26,274,088 shares).
- Confirm the current percentage of voting rights held in treasury (6.00%) for disclosure threshold calculations under FCA rules.
- Note the volume-weighted average price of 1,454.14 GBp for the August 29 transaction.
- Review the referenced Form 20-F (2024) and Q2 2025 results for detailed risk factors and broader financial context not included in this transaction report.